Acute Erythroblastic Leukemia News

Acute Erythroblastic Leukemia	Welcome, Profile Billing Logout

«1 2 3 456 »

||||||||||  lithium carbonate ER / Generic mfg.
Enrollment open:  Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  May 1, 2013
P1, N=24, Recruiting,  Sponsor: Paolo Caimi, MD
Not yet recruiting --> Recruiting

||||||||||  arsenic trioxide / Generic mfg.
New P2 trial:  Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 16, 2013
P2, N=16, Not yet recruiting,  Sponsor: Stanford University

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy:  Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (clinicaltrials.gov) -  Apr 9, 2013
P1, N=25, Completed,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Completed

||||||||||  lithium carbonate ER / Generic mfg.
New P1 trial:  Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 27, 2013
P1, N=24, Recruiting,  Sponsor: Paolo Caimi, MD

|||||||||| Enrollment open: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 12, 2013
P1, N=35, Recruiting, Sponsor: University of Southern California
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Zolinza (vorinostat) / Merck (MSD)
New P3 trial:  S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 27, 2013
P3, N=784, Recruiting,  Sponsor: National Cancer Institute (NCI)

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical:  Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) -  Feb 27, 2013
P2, N=47, Active, not recruiting,  Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| New P1 trial: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 26, 2013
P1, N=35, Recruiting, Sponsor: University of Southern California

||||||||||  MK-2206 / Merck (MSD)
Enrollment closed:  AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 20, 2013
P2, N=43, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  daunorubicin / Generic mfg., imatinib / Generic mfg.
Trial completion, Combination therapy:  Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 11, 2013
P1, N=21, Completed,  Sponsor: The Cleveland Clinic
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  mycophenolate mofetil / Generic mfg.
Trial completion, Post-transplantation:  Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 31, 2013
P2, N=0, Completed,  Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Avastin (bevacizumab) / Roche
Trial termination:  Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 22, 2013
P2, N=120, Terminated,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.

||||||||||  Cilcane (cilengitide) / Iceni Pharma
Trial termination:  Cilengitide in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 22, 2013
P2, N=70, Terminated,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Completed --> Terminated; Administratively complete.

||||||||||  Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Combination therapy:  MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P2, N=24, Completed,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. N=30 --> 24

||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion:  Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P1, N=35, Completed,  Sponsor: National Cancer Institute (NCI)
N=30 --> 24 Terminated --> Completed

||||||||||  Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Combination therapy:  MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P2, N=24, Completed,  Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Active, not recruiting --> Completed

||||||||||  sorafenib / Generic mfg.
Trial completion:  Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P1, N=48, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Terminated --> Completed

||||||||||  Zarnestra (tipifarnib) / Kura Oncology
Enrollment change:  Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 3, 2013
P1, N=30, Completed,  Sponsor: National Cancer Institute (NCI)
Terminated --> Completed N=45 --> 30

||||||||||  bortezomib / Generic mfg., daunorubicin / Generic mfg., cytarabine / Generic mfg.
Trial completion:  Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 1, 2013
P2, N=88, Completed,  Sponsor: National Cancer Institute (NCI)
N=45 --> 30 Active, not recruiting --> Completed

|||||||||| Enrollment open: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Dec 26, 2012
P1/2, N=52, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Biomarker, Enrollment change: S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=357, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting N=230 --> 357

||||||||||  cytarabine / Generic mfg.
Biomarker, Enrollment closed:  S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy (clinicaltrials.gov) -  Dec 12, 2012
P=N/A, N=310, Active, not recruiting,  Sponsor: Southwest Oncology Group
N=230 --> 357 Not yet recruiting --> Active, not recruiting

||||||||||  cytarabine / Generic mfg.
Biomarker, Trial completion:  S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Dec 12, 2012
P=N/A, N=290, Completed,  Sponsor: Southwest Oncology Group
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Completed

|||||||||| Trial completion: S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=132, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=251, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed

|||||||||| Trial completion: Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 10, 2012
P3, N=720, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P1/2 trial: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 18, 2012
P1/2, N=52, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center

|||||||||| Trial completion: S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 14, 2012
P=N/A, N=100, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed

||||||||||  sorafenib / Generic mfg.
Enrollment change:  Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) -  Nov 7, 2012
P1, N=36, Completed,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed N=55 --> 36

||||||||||  Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion:  AML02: Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia (clinicaltrials.gov) -  Nov 1, 2012
P3, N=238, Completed,  Sponsor: St. Jude Children's Research Hospital
N=55 --> 36 Active, not recruiting --> Completed

||||||||||  Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases:  Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) -  Oct 1, 2012
P1, N=5, Completed,  Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=10 --> 5

||||||||||  Leukine (sargramostim) / Partner Therap
Trial completion, Metastases:  Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) -  Oct 1, 2012
P1, N=5, Completed,  Sponsor: University of California, San Francisco
N=10 --> 5 Active, not recruiting --> Completed

|||||||||| Trial completion: A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=41, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  ispinesib (SB-715992) / Cytokinetics
Trial completion, Metastases:  SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes (clinicaltrials.gov) -  Sep 10, 2012
P1, N=40, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed:  Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) -  Sep 5, 2012
P2, N=61, Active, not recruiting,  Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  dilanubicel (NLA101) / Nohla Therap
Enrollment closed, Combination therapy:  Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Sep 3, 2012
P1, N=40, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting

||||||||||  Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion:  AML17: Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Aug 23, 2012
P3, N=472, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Suspended --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment change: Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 5, 2012
P2, N=280, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed N=40 --> 280

||||||||||  cytarabine / Generic mfg., clofarabine / Generic mfg.
New P2 trial:  A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Jul 31, 2012
P2, N=39, Active, not recruiting,  Sponsor: Comprehensive Cancer Center of Wake Forest University

||||||||||  Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion:  Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jul 12, 2012
P2, N=106, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=40 --> 280 Active, not recruiting --> Completed

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, Amsidine (amsacrine) / Kyowa Kirin
Trial completion:  Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 28, 2012
P3, N=500, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  azacitidine / Generic mfg.
Trial completion:  SAKK 30/07: Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy (clinicaltrials.gov) -  Jun 23, 2012
P2, N=47, Completed,  Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial termination, Combination therapy: Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 17, 2012
P1/2, N=6, Terminated, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Recruiting --> Terminated

|||||||||| Enrollment change, Combination therapy: Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 17, 2012
P1/2, N=6, Terminated, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Recruiting --> Terminated N=45 --> 6

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial termination:  Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 4, 2012
P2, N=16, Terminated,  Sponsor: Masonic Cancer Center, University of Minnesota
N=45 --> 6 Recruiting --> Terminated; Met protocol stop rule [i.e., extreme toxicity]

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Enrollment change:  Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 4, 2012
P2, N=16, Terminated,  Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Terminated; Met protocol stop rule [i.e., extreme toxicity] N=46 --> 16

||||||||||  cytarabine / Generic mfg., decitabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
New P2 trial:  Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (clinicaltrials.gov) -  May 28, 2012
P2, N=7, Completed,  Sponsor: Fred Hutchinson Cancer Research Center

|||||||||| Enrollment change: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 23, 2012
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=46 --> 16 N=55 --> 18

|||||||||| Enrollment closed: Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (clinicaltrials.gov) - Apr 24, 2012
P2, N=4, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=55 --> 18 Recruiting --> Active, not recruiting

|||||||||| Trial completion: High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 11, 2012
P3, N=61, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites